Litcius/Paper detail

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Nir Giladi, Roy N. Alcalay, Gary Cutter, Thomas Gasser, Tanya Gurevich, Günter U. Höglinger, Kenneth Marek, Claudio Pacchetti, Anthony H.V. Schapira, Clemens R. Scherzer, Tanya Simuni, Pascal Minini, S. Pablo Sardi, Michel Peterschmitt

2023The Lancet Neurology77 citationsDOI

Topics & Concepts

PlaceboMedicineInternal medicinePopulationNeurologyParkinson's diseaseDiseasePhysical therapyAdverse effectRating scalePsychologyPsychiatryPathologyAlternative medicineDevelopmental psychologyEnvironmental healthLysosomal Storage Disorders ResearchCarbohydrate Chemistry and SynthesisParkinson's Disease Mechanisms and Treatments
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial | Litcius